Effects of insulin-like growth factor-I and its analogue, long-R3-IGF-I, on intestinal absorption of 3-O-methyl-D-glucose are less pronounced than gut mucosal growth responses

The relationship between insulin-like growth factor-I (IGF-I) peptide-induced increases in bowel mass and functional improvement is unclear. We utilised three independent methods to investigate the effects of IGF-I peptides on intestinal absorption of the glucose analogue, 3-O-methyl-D-glucose (3MG)...

Full description

Saved in:
Bibliographic Details
Published in:Growth factors (Chur, Switzerland) Switzerland), 2002-03, Vol.20 (1), p.17-25
Main Authors: Garnaut, Sonja M, Howarth, Gordon S, Read, Leanna C
Format: Article
Language:English
Subjects:
3-O-Methylglucose - metabolism
Animals
Biological Transport
Cell Division
Dose-Response Relationship, Drug
Epithelium - metabolism
Glucose - metabolism
Glucose - pharmacology
Insulin-Like Growth Factor I - chemistry
Insulin-Like Growth Factor I - pharmacology
Intestinal Mucosa - metabolism
Intestines - metabolism
Male
Peptide Fragments - chemistry
Peptide Fragments - pharmacology
Peptides - chemistry
Peptides - pharmacology
Perfusion
Rats
Rats, Sprague-Dawley
Time Factors
Up-Regulation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The relationship between insulin-like growth factor-I (IGF-I) peptide-induced increases in bowel mass and functional improvement is unclear. We utilised three independent methods to investigate the effects of IGF-I peptides on intestinal absorption of the glucose analogue, 3-O-methyl-D-glucose (3MG) in rats. Rats received vehicle, IGF-I or the more potent analogue, long-R3-IGF-I via subcutaneously implanted mini-pump, for 7 days, at which time intestinal absorption was assessed by: (1) plasma 3MG appearance following oral gavage, (2) single-pass- or (3) recirculating-perfusion of a jejunal segment. 3MG (320 or 800 mg) was gavaged on day 7 to rats treated with vehicle, IGR-I or long-R3-IGF-I. With the lower 3MG dose, only long-R3-IGF-I increased (40%) the initial rate of 3MG appearance in plasma. IGF-I had no significant effect, whilst at the higher 3MG dose neither peptide was effective. Utilising perfusion techniques, long-R3-IGF-I, but not IGF-I, significantly increased 3MG uptake per cm of jejunum by up to 69%, although significance was lost when expressed as a function of tissue weight. Long-R3-IGF-I, but not native IGF-I, enhanced 3MG absorption from the intestinal lumen, presumably reflecting an increased mucosal mass rather than an up-regulation of specific epithelial glucose transporters.
ISSN:0897-7194